drugset
drugset / Trial / NCT06315322

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322 ↗

Phase 3 Active not recruiting 70 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.

Timeline

Start
2024-07-10
Primary completion
2029-11-16
Completion
2029-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 10 mg Oral
Subject Brivaracetam Small molecule 10 mg/ml Oral
Subject Brivaracetam Small molecule 25 mg Oral
Subject Brivaracetam Small molecule 50 mg Oral

Indications

childhood absence epilepsy juvenile absence epilepsy